Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – DCTH
The recorded move for DCTH in the trading session of this news was +2.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company Webcast
Gerard Michel, CEO, will be participating in a fireside chat. The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://delcath.com/investors/ or https://wsw.com/webcast/lytham9/dcth/2022008. The webcast will also be archived and available for replay.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at https://lythampartners.com/fall2023invreg/.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), approved for use in
Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-in-the-lytham-partners-fall-2023-investor-conference-301951598.html
SOURCE Delcath Systems, Inc.